StockData
Contineum Therapeutics, Inc. logo

Contineum Therapeutics, Inc. (CTNM) stock

CTNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30
$9.55−0.12 (-1.24%)

Close on Nov 17, 2026Market cap $359.28MP/E –Yield –

Contineum Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Contineum Therapeutics's pe ratio was 2.5× on Jul 31, 2024.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2024Jul 31, 20242.5×–

More Contineum Therapeutics figures

See a number that looks wrong?